论文部分内容阅读
目的观察噻托溴铵治疗中、重度哮喘的临床疗效及其对患者肺功能的影响。方法选择158例中、重度哮喘患者为研究对象,随机分为观察组和对照组各79例,对照组给予常规吸入布地奈德/福莫特罗粉剂,观察组在此基础上给予加用噻托溴铵吸入剂治疗,对照组用同一装置吸入安慰剂,比较两组治疗1年后的临床效果及肺功能变化。结果治疗1年后观察组ACT评分(t=3.015,P<0.05)、每周急救药物使用次数(t=1.457,P<0.05)及肺功能各指标[1 s用力呼气容积(FEV1)、1 s用力呼气率(FEV1%)、用力肺活量(FVC)、最大呼气流速峰值(PEF)及FEV1/FVC检验结果均为P<0.05]明显高于对照组。结论经规律吸入糖皮质激素和长效β受体激动剂的中、重度哮喘患者加用噻托溴铵临床疗效显著,并能有效改善患者的肺功能。
Objective To observe the clinical efficacy of tiotropium in the treatment of moderate and severe asthma and its effect on pulmonary function. Methods A total of 158 patients with moderate-to-severe asthma were selected and randomly divided into observation group (79 cases) and control group (79 cases). The control group was given routine inhalation of budesonide / formoterol powder. On the basis of this observation, Topiramate inhalation therapy, the control group inhaled the same placebo, compared two groups after 1 year of clinical efficacy and changes in lung function. Results After 1 year of treatment, the ACT score (t = 3.015, P <0.05), the number of first aid drugs weekly (t = 1.457, P <0.05) and the pulmonary function indexes (FEV1, The forced expiratory volume (FEV1%), forced vital capacity (FVC), maximum expiratory flow velocity (PEF) and FEV1 / FVC test results were significantly higher than those of the control group (P <0.05) Conclusions In patients with moderate or severe asthma who regularly inhaled glucocorticoid and long-acting beta-agonist, tiotropium has a significant clinical effect and can effectively improve pulmonary function.